Dror Mevorach - Enlivex Therapeutics CEO
ENLV Stock | ILA 519.60 21.10 3.90% |
CEO
Dror Mevorach is Chief Executive Officer, Founder, Chief Scientific Officer of Enlivex Therapeutics since 2009.
Age | 63 |
Tenure | 15 years |
Phone | (972) 2 6208070 |
Web | www.enlivex.com |
Enlivex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1888) % which means that it has lost $0.1888 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.378) %, meaning that it generated substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 3 records | CEO Age | ||
Ofer Haviv | Evogene | 51 | |
Itzhak Israel | Purple Biotech | 38 | |
Gil Efron | Purple Biotech | 51 |
Management Performance
Return On Equity | -0.38 | |||
Return On Asset | -0.19 |
Enlivex Therapeutics Leadership Team
Elected by the shareholders, the Enlivex Therapeutics' board of directors comprises two types of representatives: Enlivex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enlivex. The board's role is to monitor Enlivex Therapeutics' management team and ensure that shareholders' interests are well served. Enlivex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enlivex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Abraham Havron, Independent Director | ||
Shai Novik, Executive Chairman of the Board | ||
Dror Mevorach, Chief Executive Officer, Founder, Chief Scientific Officer | ||
Shachar Shlosberger, Chief Financial Officer | ||
Odelia BenShitrit, Head of Clinical Operations | ||
Sangwoo Lee, Director | ||
Oren Hershkovitz, Chief Executive Officer | ||
Baruch Halpert, Director | ||
Michel Habib, Director | ||
Shai MBA, Ex Chairman | ||
Pr MD, Founder Officer | ||
Veronique AmorBaroukh, Head CMC | ||
Shachar CPA, Chief Officer | ||
Gili Hart, Independent Director | ||
Brian Schwartz, Director | ||
Bernhard Kirschbaum, Director | ||
Sigal Arad, Director HR | ||
Hyun Lee, Director |
Enlivex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enlivex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.38 | |||
Return On Asset | -0.19 | |||
Current Valuation | 147.66 M | |||
Shares Outstanding | 18.41 M | |||
Shares Owned By Insiders | 12.19 % | |||
Shares Owned By Institutions | 9.53 % | |||
Price To Book | 1.23 X | |||
EBITDA | (18.74 M) | |||
Net Income | (14.47 M) | |||
Cash And Equivalents | 90.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Enlivex Stock analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |